Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept

• Proof of Concept – Evaxion’s AI-Immunology platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens
• Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies
  

COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.

Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company’s proprietary AI target discovery and development platform, AI-Immunology. Based upon a novel source of targets, endogenous retroviruses (ERVs), combined with unique data insights, Evaxion has discovered a novel concept for precision vaccines in hematological malignancies and selected solid cancers.

Tailored Precision Vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups. This marks a significant stride forward in addressing the complexities of cancers, including hematological malignancies. The discovery will potentially allow for a broader than previously expected application of vaccines in cancer therapy.

Event Details:

Title:	“Endogenous Retroviral Elements Constitute a Promising Vaccine Antigen Source for Hematological Malignancies”
Talk:	243
Session:	Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology
Session:	803
Location:	Room 30 – San Diego Convention Center
Time:	Saturday, December 9, 2:30 p.m. PDT
Presenter:	Anders Bundgård Sørensen, Project Director of Research and Discovery

About ERVs